Introduction {#s1}
============

Behçets' disease (BD) is a rare and idiopathic multisystem inflammatory disorder with diverse clinical manifestations, including recurrent oral and genital ulcers, cutaneous vascular lesions, central nervous system, and ocular impairment ([@B19]; [@B47]; [@B52]). The incidence of BD varies according to geographical location, with high prevalence along the ancient silk road (15--420 cases per 100,000 population) and very low prevalence in North America (0.12--0.33 cases per 100,000 population) and in Western countries ([@B8]; [@B39]).

Ocular involvement occurs in 30--70% of cases of BD ([@B17]) and usually presents as chronic, relapsing uveitis or retinal vasculitis, which result in severe complications, such as intractable macular edema, retinal vessels obstruction, nerve fibers atrophy, and opacity of optical medium. About 25% of patients of BD-associated uveitis become blind as a result of irreversible vision impairment after multiple recurrences. It is urgent to control the inflammation and reduce the remission with effective therapy ([@B27]; [@B23]; [@B17]).

It is recommended to use systematic corticosteroids (CSs) together with immunosuppressive agents, such as azathioprine (AZA), cyclosporin (CsA), and methotrexate (MTX) for the treatment of BD-associated uveitis ([@B20]; [@B28]). Despite successfully decreasing inflammation in some BD-associated uveitis, the combined treatment often fails to prevent relapses in a majority of those patients. What's more, local and systemic side effects occur when large-dose steroids are used, and relapses are frequently seen after discontinuation of steroids in refractory patients ([@B24]; [@B29]). New treatment strategies are urgently needed.

Biological therapies, such as the inhibition of TNF-α, have emerged as preferred treatment alternatives for treatment ([@B29]). As we all know that TNF-α is the major pre-inflammation factor involving autoimmune diseases. Anti-TNF-α agents are recommended as a first- or second-line therapy or even as a rescue therapy after the failure of conventional drugs in chronic noninfectious uveitis with diverse etiologies ([@B29]). Many previous studies have reported the efficacy and safety of anti-TNF-α agents, such as infliximab (IFX) and adalimumab (ADA) in chronic noninfectious uveitis ([@B43]; [@B4]; [@B11]; [@B33]; [@B45]; [@B34]). Recently, two Randomized Controlled Trials (RCTs), VISUAL I ([@B22]) and VISUAL II ([@B37]) have been conducted to evaluate the therapy of adalimumab in intermediate, posterior and pan-uveitis related different etiologies. What's more, ADA was approved in non-infectious uveitis by US FDA[^1^](#fn1){ref-type="fn"} and European Medicines Agency (EMA)[^2^](#fn2){ref-type="fn"} in 2016, also approved by China National Medical Products Administration (NMPA) in 2020.

However, the heterogeneity of drug response is still existed among different types of uveitis and the prognosis of BD-associated uveitis is usually worse than other etiological uveitis. As we know, until now there is few RCT or systematic review evaluating the efficacy and safety of anti-TNF-α agents specifically on BD-related uveitis, so it is needed to get more evidence for ophthalmologists to make right treatment decision. Based on the above consideration, we performed a systematic literature review and meta-analysis to summarize the currently available evidence regarding the effectiveness and safety of anti-TNF-α therapy in the treatment of BD-associated uveitis.

Methods {#s2}
=======

A systematic review and meta-analysis was conducted to integrate information presented in studies on the effectiveness and safety of anti-TNF-α therapy in the treatment of uveitis associated with BD published in the past 10 years. This review was carried out following the preferred reporting items for systematic review and meta-analysis (PRISMA) statements and the protocol followed the PRISMA-Protocol guidelines ([@B40]).

Search Strategy {#s2_1}
---------------

We searched the electronic Medline, Embase, and Cochrane Library databases for papers published from January 2010 to September 2019. The search was restricted in the abstract\\keywords\\title fields to cut down on irrelevant literature. The index words were "Behcet" or "Behcet's" or "Behcet disease" or "Behcet' disease" or "Behcet's disease" crossed with "anti tumor necrosis factor alpha" or "anti TNF alpha" or "TNF alpha inhibitors" or "tumor necrosis factor alpha inhibitors" or "TNF-α inhibitors" or "anti-TNF-α" or "adalimumab" or "infliximab". Ocular involvement was searched by "uveitis" or "iridocyclitis" or "retinitis" or "retinal vasculitis" or "panuveitis". Prospective open-label trials, uncontrolled case series reports and summaries of conferences were included to provide more evidence.

Inclusion Criteria {#s2_2}
------------------

The inclusion criteria were defined as follows: 1) BD-associated uveitis studies or studies including data of BD-associated uveitis which could be extracted separately, 2) patients received anti-TNF-α therapy, 3) the mean follow-up time was at least 6 months, and 4) at least 10 patients were included in the study to avoid bias.

It is generally recommended anti-TNF-α agents to be used for more than 6 months in patients of chronic non-infectious uveitis. What's more, in most studies, the examinations and evaluations were done every 6 months during follow-up time.

Study Selection and Quality Evaluation {#s2_3}
--------------------------------------

Two independent authors (YH and WS) identified the relevant studies according to the inclusion criteria. The quality and risk of bias of each trial was evaluated using the Newcastle-Ottawa Scale ([@B50]). Any disagreements were resolved by discussion and, if required, referred to a third reviewer.

Outcome Measures {#s2_4}
----------------

The effectiveness outcome measures included the proportion of patients with inflammation remission, visual acuity (VA) improvement, central macular thickness (CMT) decrease and CS-sparing effects.

The safety outcome measures were the number and severity of adverse events (AEs). AEs included, but were not limited: 1) new-onset or reactivated infections, 2) gastrointestinal discomfort, 3) injection site or allergic reactions, 4) immunogenicity-related AEs.

Data Extraction and Analysis {#s2_5}
----------------------------

The evaluation of outcomes was performed for each patient. Descriptions of dichotomous outcome were graded dichotomously by "yes" or "no" responses. We retrieved the total number of included patients and the number who experienced the outcome. We reported all proportions of patients who experienced outcomes and related 95% confidence intervals (95% CIs). Dichotomous data were preferentially reported in this review as risk ratios using a Mantel-Haenszel fixed-effects (FE) model and 95% CIs. The pooled prevalence rates and their 95% CIs were estimated using a random or fixed effects model. For continuous outcomes, we retrieved the mean and standard deviation (SD). The pooled mean and SD were estimated using a random or fixed effects model. A random-effects model was used if the statistical heterogeneity \> 50% and p \< 0.1. Otherwise, a fixed-effects model was used.

All analyses were performed in STATA 12. Meta-analysis was utilized to identify the pooled rates of inflammation remission, VA improvement, CMT decrease, and CS-sparing effects. Safety outcomes were analyzed by qualitative synthesis with a focus on the description instead of meta-analysis. Subgroup analyses were conducted to explore the sources of between-study heterogeneity. The subgroups were divided by study location, study design, the duration of follow-up time and the choice of anti-TNF-α agents. Potential publication bias was assessed by Egger's test and presented in funnel plots.

Results {#s3}
=======

Study Selection and Characteristics {#s3_1}
-----------------------------------

The search of literature produced 504 records (MEDLINE: 167, Embase: 313, CENTRAL: 24). No additional records were identified through other sources or manual searches. After duplicate removal and title and abstract screening, 53 articles were identified and examined in detail. Finally, we included 18 articles in the meta-analysis. A flow diagram demonstrated the process of study selection ([**Figure 1**](#f1){ref-type="fig"}). Most studies (15/18) were retrospective, and only three studies were prospective. The anti-TNF-α agents researched in these studies included adalimumab and infliximab. The quality evaluation of the included studies was done according to the Newcastle-Ottawa Scale.

![Flow diagram demonstrating the study selection process. ADA, adalimumab; IFX, infliximab.](fphar-11-00941-g001){#f1}

The characteristics of these studies ([@B2]; [@B26]; [@B7]; [@B38]; [@B1]; [@B3]; [@B5]; [@B18]; [@B35]; [@B6]; [@B21]; [@B46]; [@B12]; [@B14]; [@B10]; [@B13]; [@B32]; [@B25]; [@B51]) were described in [**Table 1**](#T1){ref-type="table"} and [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. The 18 articles comprised 968 patients in total and the number of patients in each study ranged from 11 to 164. Excluding one study which enrolled 20 patients did not give sex information, 64.66% (613/948) of patients in other 17 studies were male. The mean ages ranged from 24.3 to 45.1 years and the mean follow-up time ranged from 0.9 to 6.44 years.

###### 

Study characteristics of the included studies.

  First author (year)   Location       Continent   Study design          Anti-TNF-α agents   Sample size   Male (%)     Mean age (SD)   Remission (%)[^a^](#fnT1_1){ref-type="table-fn"}   Follow-up (years)[^b^](#fnT1_2){ref-type="table-fn"}   Quality score[^c^](#fnT1_3){ref-type="table-fn"}
  --------------------- -------------- ----------- --------------------- ------------------- ------------- ------------ --------------- -------------------------------------------------- ------------------------------------------------------ --------------------------------------------------
  [@B1]                 Saudi Arabia   Asia        Retrospective study   IFX                 19            18 (94.7)    25.6 (7.8)      9 (47.4)                                           3.67                                                   7
  [@B2]                 Saudi Arabia   Asia        Retrospective study   ADA                 11            11 (100.0)   28.4 (5.6)      10 (90.9)                                          0.9                                                    4
  [@B3]                 Spain          Europe      Retrospective study   IFX, ADA            63            36 (57.1)    38.9 (9.0)                                                         2                                                      5
  [@B5]                 Spain          Europe      Retrospective study   IFX, ADA            108           59 (54.6)    38.2 (10.4)                                                        2                                                      6
  [@B5]                 Spain          Europe      Retrospective study   IFX, ADA            124           68 (54.8)    38.6 (10.4)     84 (67.7)                                          1                                                      8
  [@B7]                 Italy          Europe      Prospective study     IFX                 50            20 (40.0)    37.5 (12.3)     31 (62.0)                                          2                                                      8
  [@B51]                Turkey         Asia        Retrospective study   IFX                 20            13(65.0)     27.9(4.2)       16 (80.0)                                          1.73                                                   4
  [@B12]                Spain          Europe      Retrospective study   IFX                 100           54 (54.0)    40.7 (10.1)                                                        1                                                      4
  [@B13]                Egypt          Africa      Prospective study     IFX                 20            17 (85.0)    31.8 (9.1)      14 (70.0)                                          1.17                                                   6
  [@B14]                Italy          Europe      Retrospective study   ADA                 40            22 (55.0)    41.9 (12.0)     21 (95.5)                                          1                                                      8
  [@B18]                Turkey         Asia        Retrospective study   IFX                 43            33 (76.7)    31.0 (8.4)      11 (34.4)                                          2.42                                                   5
  [@B21]                Italy          Europe      Retrospective study   ADA                 12            11 (91.7)    24.3 (8.6)      11 (91.7)                                          1.75                                                   7
  [@B25]                Japan          Asia        Retrospective study   IFX                 11            8 (72.7)     45.1 (8.6)                                                         2                                                      7
  [@B26]                Japan          Asia        Retrospective study   IFX                 14            12 (85.7)    38.0            8 (57.1)                                           1.58                                                   7
  [@B32]                Spain          Europe      Retrospective study   ADA                 74            39 (52.7)    38.7 (11.3)     65 (87.8)                                          2.89                                                   8
  [@B35]                Spain          Europe      Retrospective study   IFX, ADA            32            16 (50.0)    39.0 (11.9)     28 (87.5)                                          6.44                                                   6
  [@B38]                Japan          Asia        Prospective study     IFX                 63            56 (88.9)    37.4 (11.6)     21 (43.8)                                          1                                                      5
  [@B46]                Japan          Asia        Retrospective study   IFX                 164           133 (81.1)   40.0 (11.7)     67 (40.9)                                          2.74                                                   8

NA, not available; ADA, adalimumab; IFX, infliximab.

The number of patients with ocular remission (the proportion of patients with ocular remission).

The mean duration of follow-up.

Study quality was assessed using the Newcastle-Ottawa Scale. The score indicates the percentage of items met by each included study.

Meta-Analysis and Subgroup Analysis {#s3_2}
-----------------------------------

The results of the meta-analysis and subgroup analysis were demonstrated in [**Table 2**](#T2){ref-type="table"}. The pooled results included the rate of inflammation remission, VA improvement, CMT decrease, and CS-sparing effects. Heterogeneity was high in the analysis of inflammation remission (*I^2^ =*89.3%), but was not detected in the subgroups of prospective study group (*I^2^ =*59.2%) and ADA therapy group (*I^2^ =*0.0%). Similarly, heterogeneity was high in the analysis of VA improvement (*I^2^ =*86.6%), but was not detected in the subgroups of Europe (*I^2^ =*0.0%), prospective study group (*I^2^ =*0.0%), and ADA therapy group (*I^2^ =*22.2%). The subgroup analysis indicated the study location, study design and the kind of anti-TNF-α agent contributed to such heterogeneity exited.

###### 

The results of the meta-analysis and subgroup analysis.

                                                                 No. of studies        Pooled effect sizes (95% CI)   Heterogeneity            *P* of Egger's for publication bias             
  -------------------------------------------------------------- --------------------- ------------------------------ ------------------------ ------------------------------------- --------- --
  **Inflammation remission (%)**                                 15                    68.2 (59.1, 78.8)              89.3                     \<0.001                               0.014     
  Study location                                                                                                                                                                               
                                                                 Asia                  7                              54.3 (39.7, 74.4)        88.5                                  \<0.001   
                                                                 Europe                6                              82.1 (72.6, 92.7)        82.9                                  \<0.001   
  Study design                                                                                                                                                                                 
                                                                 Retrospective study   11                             71.3 (60.9, 83.5)        90.2                                  \<0.001   
                                                                 Prospective study     3                              58.3 (45.6, 74.6)        59.2                                  0.129     
  Follow up (months)                                                                                                                                                                           
                                                                 \<24                  8                              75.4 (64.2, 88.4)        83.1                                  \<0.001   
                                                                 ≥24                   6                              58.7 (43.7, 78.8)        93.5                                  \<0.001   
  Anti TNF agents                                                                                                                                                                              
                                                                 IFX                   8                              53.7 (43.1, 66.8)        77.6                                  \<0.001   
                                                                 ADA                   4                              91.3 (86.4, 96.5)        0.0                                   0.639     
                                                                 IFX, ADA              2                              76.9 (59.8, 98.8)        87.3                                  \<0.001   
  **Corticosteroid suspended**                                   5                     38.4 (22.8, 64.6)              85.9                     \<0.001                               0.116     
  Study location                                                                                                                                                                               
                                                                 Asia                  2                              44.4 (16.1, 100.0)       94.2                                  \<0.001   
                                                                 Europe                3                              34.3 (17.8, 66.0)        76.0                                  \<0.001   
  Follow up (months)                                                                                                                                                                           
                                                                 \<24                  2                              30.5 (7.9, 100.0)        87.9                                  \<0.001   
                                                                 ≥24                   3                              42.3 (21.8, 82.1)        89.6                                  \<0.001   
  Anti TNF agents                                                                                                                                                                              
                                                                 IFX                   2                              44.4 (16.1, 100.0)       94.2                                  \<0.001   
                                                                 ADA                   2                              30.5 (7.9, 100.0)        87.9                                  \<0.001   
  **Corticosteroid tapered**                                     3                     33.9 (16.4, 69.8)              71.8                     0.029                                 0.210     
  **CMT decrease(μm)** [^**a**^](#fnT2_1){ref-type="table-fn"}   5                     -112.7 (-152.6, -72.8)         70.2                     0.009                                 0.911     
  Follow up (months)                                                                                                                                                                           
                                                                 \<24                  2                              -107.8 (-187.7, -27.8)   87.0                                  \<0.001   
                                                                 ≥24                   3                              -117.1 (-169.0, -65.2)   61.5                                  0.021     
  Anti TNF agents                                                                                                                                                                              
                                                                 IFX                   2                              -102.1 (-177.0, -27.2)   76.8                                  \<0.001   
                                                                 IFX, ADA              3                              -121.1 (-170.7, -71.4)   67.2                                  0.011     
  **VA improvement**                                             8                     60.3 (47.2, 77.0)              86.6                     \<0.001                               0.206     
  Study location                                                                                                                                                                               
                                                                 Asia                  5                              44.1 (31.0, 62.7)        72.6                                  0.054     
                                                                 Europe                2                              86.8 (77.7, 96.9)        0.0                                   0.391     
  Study design                                                                                                                                                                                 
                                                                 Retrospective study   6                              50.7 (35.4, 72.6)        88.0                                  \<0.001   
                                                                 Prospective study     2                              82.3 (72.9, 92.9)        0.0                                   0.784     
  Anti TNF agents                                                                                                                                                                              
                                                                 IFX                   6                              52.5 (38.5, 71.4)        87.6                                  \<0.001   
                                                                 ADA                   2                              86.5 (71.0, 100.0)       22.2                                  0.186     
  Follow up (months)                                                                                                                                                                           
                                                                 \<24                  4                              76.2 (59.5, 97.7)        63.8                                  0.015     
                                                                 ≥24                   4                              49.3 (33.0, 73.6)        90.9                                  \<0.001   

ADA, adalimumab; IFX, infliximab; CS, corticosteroid; CMT, central macular thickness; VA, visual acuity.

Difference between before and after treatment.

In addition, the presence of publication bias was not detected across the studies reporting (P \> 0.1) other than in the analysis of inflammation remission (P=0.014). The funnel plots were demonstrated in [**Supplementary Figure 1**](#SF1){ref-type="supplementary-material"}, and the P values of Egger's test were list in [**Table 2**](#T2){ref-type="table"}.

Inflammation Remission {#s3_3}
----------------------

Fourteen studies ([@B2]; [@B26]; [@B7]; [@B38]; [@B1]; [@B18]; [@B35]; [@B6]; [@B21]; [@B46]; [@B14]; [@B13]; [@B32]; [@B51]) including 642 patients of BD-associated uveitis were evaluated for the rate of inflammation remission after anti-TNF-α therapy. The total number of included patients and the number who reached inflammation remission during the follow-up time in each study were retrieved. A random effects model was used for the test of heterogeneity (89%, p\<0.01). The overall pooled remission rate was 68%, with a 95% CI of 0.59--0.79 ([**Figure 2**](#f2){ref-type="fig"}). The forest plot showed that the diamond marker did not intersect 1, suggesting the anti-TNF-α therapy reached a 68% inflammation remission rate with significant difference.

![Forest plot of the inflammation remission rate after anti-tumor necrosis factor-alpha (TNF-α) treatment.](fphar-11-00941-g002){#f2}

Visual Acuity Improvement {#s3_4}
-------------------------

A total of eight studies ([@B2]; [@B26]; [@B7]; [@B1]; [@B18]; [@B21]; [@B46]; [@B13]) involving 319 patients presented the number of patients with improvement in VA after the intervention. The overall pooled proportion of patients with improved VA was 60%, with a 95% CI of 0.47--0.77. The test of heterogeneity was 87% (p\<0.01), suggesting that a random-effects model was preferred. The forest plot showed that the diamond marker did not intersect 1, suggesting that the 60% pooled prevalence was significantly higher than 0 ([**Figure 3**](#f3){ref-type="fig"}).

![Forest plot of visual acuity (VA) improvement after anti-TNF-α treatment.](fphar-11-00941-g003){#f3}

Bejerano, C. ([@B3]) reported that VA improved from 0.5 ± 0.3 at baseline to 0.7 ± 0.3 after 2 years (p\<0.001) in 63 patients/110 affected eyes. El Garf, A. K. ([@B13]) presented 36 affected eyes (16 bilateral and 4 unilateral) in which VA significantly improved (p \<0.05) from 0.1 ± 0.09 at baseline to 0.6 ± 0.2 at week 8 and 0.8 ± 0.2 at week 32, respectively. There was no additional improvement at week 56, when the VA was still 0.8 ± 0.2. In Takeuchi's study ([@B46]) in 2014, the mean best corrected visual acuity (BCVA) was recorded as the logarithm of the minimum angle of resolution (logMAR). The VA significantly improved when the duration of infliximab treatment ranged from 12 to 48 months (P \< 0.05), but did not improve when the patients needed more than 48 months treatment. Because the values of VA were recorded in different methods, like the decimal vision and logMAR vision, a meta-analysis on the amount of VA improvement was not conducted.

Central Macular Thickness Decrease {#s3_5}
----------------------------------

The changes of CMT were evaluated and analyzed in five studies ([@B1]; [@B3]; [@B5]; [@B6]; [@B12]). The pooled results suggested that CMT decreased by 112.70 μm, with a 95% CI of 72.8--153 μm, indicating significant difference. A random effects model was used for the test of heterogeneity (70%, p\<0.01) ([**Figure 4**](#f4){ref-type="fig"}).

![Forest plot of central macular thickness (CMT) reduction after anti-TNF-α treatment.](fphar-11-00941-g004){#f4}

Corticosteroid-Sparing Effects {#s3_6}
------------------------------

Information on the CS-sparing were extracted and analyzed. Fifty-five (33.95%) of 162 patients completely discontinued CS in five articles ([@B1]; [@B35]; [@B21]; [@B46]; [@B14]), and 16 (28.07%) of 57 patients had a CS dose reduction in three articles ([@B2]; [@B21]; [@B14]). The pooled proportions of CS-suspended and CS-tapered patients were 38% with a 95% CI of 0.23--0.65 and 34% with a 95% CI of 0.16--0.70, respectively. The differences were statistically significant because the diamond markers did not intersect 1 in the forest plot ([**Figure 5**](#f5){ref-type="fig"}).

![Forest plot of the corticosteroid (CS)-sparing effects of anti-TNF-α treatment. The analysis was conducted by dividing studies into "suspended" and "tapered" according to changes in the CS dosage.](fphar-11-00941-g005){#f5}

Only two studies mentioned the dosage in detail. The mean daily dose of CS decreased from 26.87 to 3.33 mg/day (p=0.002) in Interlandi E. ([@B21]) and from 18.25 mg (range 12.5--17.5 mg) to 7.9 mg (range 5--10 mg) (P\<0.05) in Bawazeer A. ([@B2]) during anti-TNF-α therapy.

Adverse Events {#s3_7}
--------------

A total of 14 studies ([@B26]; [@B1]; [@B3]; [@B5]; [@B18]; [@B35]; [@B6]; [@B46]; [@B12]; [@B14]; [@B13]; [@B32]; [@B25]; [@B51]) included safety information with more than 109 patients ([**Table 3**](#T3){ref-type="table"}). According to the available data, 22 patients (2.62%) experienced severe AEs. The result of incidence rate excluded two studies in which information on severe AEs was not available. The severe AEs included severe infusion reactions (n=3), melanoma (n=1), lymphoma (n=3), pneumonia (n=6), bacteremia (n=3), and tuberculosis (n=6). The most frequently reported mild AEs were infusion reactions (rash, itchiness, or respiratory distress), upper respiratory inflammation, gastroenteritis, and urinary tract infections.

###### 

Adverse events reported in the included studies.

  First author (year)   Sample size (n)   Follow-up (years)[^a^](#fnT3_1){ref-type="table-fn"}   AEs (n)   Severe AEs (%)[^b^](#fnT3_2){ref-type="table-fn"}   Detailed safety information
  --------------------- ----------------- ------------------------------------------------------ --------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B1]                 19                3.67                                                   1         1 (5.26)                                            One patient developed a severe infusion reaction during the 19th scheduled infusion
  [@B2]                 11                0.9                                                    0         0 (0)                                               None
  [@B3]                 63                2                                                      1         1 (1.59)                                            Miliary TB in 1 patient at month 1 after the onset of IFX.
  [@B5]                 108               2                                                      NA        NA                                                  NA
  [@B5]                 124               1                                                      NA        3 (2.4)                                             Minor side effects: mild infusion reactions and local reactions (pain and erythema). Severe AEs were observed in 3 case: one patient had miliary TB after 1 month of IFX, another was diagnosed with non-Hodgkin's lymphoma in month 6 of ADA treatment, and one patient who died was diagnosed with melanoma in month 3 of treatment with ADA.
  [@B7]                 50                2                                                      0         0 (0)                                               None
  [@B51]                20                1.73                                                   3         NA                                                  Three patients were switched to a different agent because of AEs.
  [@B12]                100               1                                                      4         4 (4)                                               Severe AEs were lymphoma (n=1), pneumonia (1), and bacteriemia (2 by *Escherichia coli*)
  [@B13]                20                1.17                                                   8         0 (0)                                               Mild infusion reactions in 4 patients, frequent urinary tract infections in 1 patient, and frequent upper airway infections in 3 patients
  [@B14]                40                1                                                      1         1 (2.27)                                            One severe AE: pneumonia.
  [@B18]                43                2.42                                                   5         4 (9.30)                                            Pulmonary TB in 3 patients (in month 17, 32, and 46 of IFX treatment). Pneumonia in 1 patient and depression in 1 patient.
  [@B21]                12                1.75                                                   0         0 (0)                                               None
  [@B25]                11                2                                                      4         0 (0)                                               Urinary tract infection in 1 patient and significant cataract progression in 1 patient. Two patients exhibited transient elevation of serum creatinine levels.
  [@B26]                14                1.58                                                   10        0 (0)                                               Infusion reactions (rash, itchiness and/or respiratory distress) in 4 patients and common cold symptoms in 5 patients. One patient had suspected bacterial pharyngitis that responded to antibiotic therapy.
  [@B32]                74                2.89                                                   4         4 (5.41)                                            Severe AEs were found in 4 patients (lymphoma, pneumonia, severe local reaction at the injection site, and bacteremia by *Escherichia coli*; 1 each).
  [@B35]                32                6.44                                                   3         2(5.25)                                             One severe infusion reaction, 1 case of pulmonary tuberculosis, and 1 case of prostatitis
  [@B38]                63                1                                                      NA        0(0)                                                Urticaria and rash, infusion reactions and decreased blood pressure were observed, but the number with each AE was not mentioned.
  [@B46]                164               2.74                                                   65        2 (1.22)                                            AEs were observed in 65 cases and included infusion reaction (21% incidence), upper respiratory inflammation (4% incidence) and gastroenteritis (3% incidence). Pneumonia occurred in 2 patients (3%).[^c^](#fnT3_3){ref-type="table-fn"}

NA, not available; AEs, adverse events; IFX, infliximab; ADA, adalimumab; TB, tuberculosis.

The mean duration of follow-up.

The percentage of severe AEs observed in all subjects in each study, marked as a number (percentage).

The incidence indicates the proportion of patients with one particular reaction out of all of the AEs reported in this study.

Discussion {#s4}
==========

TNF-α is a pro-inflammatory cytokine produced by Th1 lymphocytes and macrophages and is expressed at a significantly higher level in BD patients compared to in healthy controls ([@B9]; [@B41]). It has been reported that TNF-α plays a key role in the development and persistence of uveitis in BD ([@B30]). Therefore, anti-TNF-α therapy may provide good efficacy in BD-associated uveitis ([@B15]; [@B42]; [@B43]). In this meta-analysis, we summarized the available evidence on the use of anti-TNF-α in the treatment of BD-associated uveitis.

We presented a pooled proportion for the inflammation remission rate of 68%, which was lower than the results presented in other reviews. Shuai Ming et al. ([@B36]) presented that the proportions of activity controlled were 74% and 79% in non-infectious uveitis with adalimumab at ≤6 and ≥12 months follow-up respectively. The slightly lower rate obtained in our review may due to that the refractory of BD-associated uveitis than other cases. Furthermore, Simonini et al ([@B44]) summarized the inflammation remission rate of anti-TNF-α treatment in childhood BD-associated uveitis with a pooled proportions of 87% in the ADA group and 72% in the IFX group, which were both higher than our data. In consideration of the patients' age of our review (24.3--45.1 years), the children could have better inflammation control than adults. Some retrospective ([@B16]; [@B48]) surveys had shown that ocular complications and, notably, blindness were less frequent in the children-onset group than in the adult group. According this review and analysis it was concluded that BD-associated ocular inflammation can be effectively controlled by anti-TNF-α agents.

This review indicated the pooled rate of VA improvement was 60%. There was a point we should indicated that this rate did not include patients with stable vision. Hence, the proportion of patients with VA preservation (stable VA and improved VA) should be higher, as was found in Shuai Ming's analysis ([@B36]). In his analysis, ADA effectively preserved VA in 88.8% of the patients.

The decrease of CMT was as much as 112.70 μm by anti-TNF-α agents invention, which indicated that both structure and function of macular could therefore be substantially improved. The anti-TNF-α treatment had prominent efficacy in refractory CME related to BD as reported ([@B1]; [@B6]). Markomichelakis NN ([@B31]) conducted a study on the efficacy of infliximab for treatment of chronic CME due to uveitis. He included 10 patients with a long-standing CME but without active inflammation at the time of infliximab infusion. The macular thickness was reduced from 428 ± 138 μm to 219 ± 51 μm at 2 months. It suggested that TNF-α might play a pathogenetic role in chronic CME, and the mechanism of improving CME of anti-TNF-α might be not directly related to inflammation.

We categorized the outcome of CS-sparing effects into two subtypes: the proportion of patients of CS-suspended and of CS-tapered. In this analysis, 38% of patients were CS-suspended and 34% were CS-tapered. The mean daily dose of CS decreased from 26.87 to 3.33 mg/day in the report of Interlandi E. ([@B21]) and from 18.25 to 7.9 mg in the report of Bawazeer A. ([@B2]). We could infer from these findings that many patients obtained benefit from the CS-sparing effects of the anti-TNF-α treatment, which was associated with not only better outcomes and but also better tolerability.

The results mentioned above suggested that anti-TNF-α provided satisfactory control of ocular inflammation, improved visual prognosis and allowed good preservation of macular structural integrity. It was consistent with the results in a meta-analysis by Urruticoechea-Arana A et al. ([@B49]). He presented that patients treated with anti-TNF-α agents had a lower risk of uveitic flare or visual impairment over the long-term than those in conventional therapy group. What's more, treatment with anti-TNF-α drugs yielded a significant CS-sparing effect, which reduced the occurrence of steroid-related complications such as glaucoma, cataract, obesity, hirsutism, gastrohelcosis, and growth retardation. It seemed that anti-TNF-α agents would have positive effects on long-term prognosis for BD-associated uveitis.

However, it was necessary to address the safety of anti-TNF-α treatment here. In this review, we found that 22 patients (2.62% of all included patients) experienced severe AEs ([@B1]; [@B3]; [@B18]; [@B35]; [@B6]; [@B12]; [@B14]; [@B32]), while some minor AEs such as infusion reactions (rash, itchiness, or respiratory distress) and gastroenteritis happened frequently. Infectious AEs, such as tuberculosis, pneumonia, bacteremia, urinary tract, and upper airway infections, were the main severe AEs. These may result from the suppression of the immune system by anti-TNF-α treatment, so we should be alert to signals of early infection so that in-time intervention cloud be implemented, especially for elder patients. In addition, melanoma and lymphoma were reported in the review, so ophthalmologists should be aware of these rare but fatal AEs. Better understanding of the drug-related complications calls for studies with long-term duration of follow-up.

Conclusions {#s5}
===========

In conclusion, by reviewing and analyzing the 18 articles, the results presented that anti-TNF-α treating was one of effective therapeutic method for BD-associated uveitis. However, clinicians should pay more attention to prevent patients from having severe AEs, especially for elder patients. Fortunately, the incidence of severe AEs was not very high.

Limitation {#s5_1}
----------

Several limitations of our analyses must be mentioned. First of all, there were few RCT articles for us to review and only 3/18 articles were prospective uncontrolled research. Differences in follow-up durations and observation endpoints across different trials may have affected the results. Secondly, high heterogeneity was observed in our analysis. We found that study location, study design, and the kind of anti-TNF-α agents (ADA or IFX) contributed to the heterogeneities. The presence of publication bias detected in the analysis of inflammation remission was also a limitation in our analysis ([**Table 2**](#T2){ref-type="table"} and [**Supplementary Figure 1**](#SF1){ref-type="supplementary-material"}). It is an urgent for more high-quality and large-scale RCTs to better evaluate the efficacy and safety profile of anti-TNF-α treatment in patients with BD-associated uveitis.
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Funnel plots for publication bias using Egger's text. The Egger's test of A) the analysis of inflammation remission rate, B) the analysis of corticosteroid-suspended rate, C) the analysis of corticosteroid-tapered rate, D) the analysis of central macular thickness decrease and E) the analysis of improved visual acuity.
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